Avid bioservices completes construction of new, world-class cell and gene therapy development and manufacturing facility

Newly launched cgmp manufacturing suites undergoing final environmental monitoring and performance qualification with grand opening planned for january 2024 completion of cgt facility brings company's total revenue generating capacity to up to approximately $400 million annually tustin, calif., oct. 17, 2023 (globe newswire) -- avid bioservices, inc. (nasdaq:cdmo), a dedicated biologics contract development and manufacturing organization (cdmo) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that it has completed construction of cgmp manufacturing suites within its new, world-class cell and gene therapy (cgt) development and cgmp manufacturing facility as scheduled.
CDMO Ratings Summary
CDMO Quant Ranking